Takeda押注6億美元與Insilico合作自動化早期藥物發現
takeda與insilico medicine簽署了價值6億美元的協議，以利用其pharma.ai平台進行靶點發現。這表明製藥巨頭正開始將風險較高的早期研發外包給ai專家。
takeda entered a strategic collaboration with insilico medicine, potentially worth $600m, to deploy ai in identifying new drug targets and small molecule generation. the agreement leverages insilico's pharma.ai suite, specifically its generative biology and chemistry tools, to de-risk takeda's discovery pipeline. the partnership highlights a trend where large pharmaceutical firms outsource the most speculative part of r&d to specialized ai vendors rather than building internal tech. successful execution here could force competitors to abandon internal platform development in favor of similar outsourcing models.